7
Participants
Start Date
June 27, 2019
Primary Completion Date
March 18, 2021
Study Completion Date
March 18, 2021
Nivolumab
"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
UPMC Hillman Cancer Center, Pittsburgh
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus
St. Joseph Mercy Hospital, Ann Arbor
University of Wisconsin Clinical Science Center, Madison
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
University of Chicago Medical Center, Chicago
Providence Cancer Institute Franz Clinic, Portland
Massachusetts General Hospital, Boston
Dartmouth Hitchcock Norris Cotton Cancer Center, Lebanon
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Alliance Foundation Trials, LLC.
OTHER